TIDMDDDD
4d Pharma PLC
02 August 2021
THIS IS A REACH ANNOUNCEMENT AND THE INFORMATION CONTAINED IS
NOT CONSIDERED TO BE MATERIAL OR TO HAVE A SIGNIFICANT IMPACT ON
MANAGEMENT'S EXPECTATIONS OF THE COMPANY'S PERFORMANCE. REACH IS AN
INVESTOR COMMUNICATION SERVICE AIMED AT ASSISTING LISTED AND
UNLISTED (INCLUDING AIM QUOTED) COMPANIES TO DISTRIBUTE
NON-REGULATORY NEWS RELEASES INTO THE PUBLIC DOMAIN. INFORMATION
REQUIRED TO BE NOTIFIED UNDER THE AIM RULES FOR COMPANIES, MARKET
ABUSE REGULATION OR OTHER REGULATION WOULD BE DISSEMINATED AS AN
RNS REGULATORY ANNOUNCEMENT AND NOT ON REACH.
4D pharma Announces Two Presentations at European Society for
Medical Oncology (ESMO) Congress 2021
Leeds, UK - August 2, 2021 - 4D pharma plc (AIM: DDDD, NASDAQ:
LBPS) , a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs), a novel class of drug derived from
the microbiome, today announces two poster presentations at the
European Society for Medical Oncology (ESMO) Congress, held from
September 16-21, 2021. The two e-posters will be available from
07:30 BST (02:30 ET) on September 16, 2021.
Poster presentation details are as follows:
Presentation Title : Baseline biomarkers associated with
clinical benefit in patients with solid tumors refractory to immune
checkpoint inhibitors (ICIs) treated with live biotherapeutic
MRx0518 in combination with pembrolizumab
Presenting Author : Dr. Edwin R. Parra, Assistant Professor,
Department of Translational Molecular Pathology, University of
Texas MD Anderson Cancer Center
Presentation Number : 1024P
Presentation Title : Neoadjuvant MRx0518 treatment is associated
with significant gene and metagene signature changes in solid
tumours
Presenting Author : Dr. Mark P. Lythgoe, Academic Clinical
Fellow in Medical Oncology and Pharmacist, Imperial College
London
Presentation Number : 543P
About MRx0518
MRx0518 is single strain Live Biotherapeutic product in
development for the treatment of cancer. It is delivered as an oral
capsule and stimulates the body's immune system, directing it to
produce cytokines and immune cells that are known to attack tumors.
It is currently being evaluated in three clinical trials in cancer
patients. MRx0518-I-001 is a neoadjuvant monotherapy study in a
variety of solid tumors and is being conducted at Imperial College
(London, UK). MRx0518-I-002 is in combination with KEYTRUDA
(pembrolizumab) in patients who have previously progressed on anti
PD-1 therapies. The Coordinating Investigator of the study is at
The University of Texas MD Anderson Cancer Center, Houston, USA,
with multiple additional sites in the US. The study is being
conducted in collaboration with MSD, the tradename of Merck &
Co., Inc., Kenilworth, NJ, USA. MRx0518-I-003 is in combination
with preoperative radiotherapy in resectable pancreatic cancer. A
fourth clinical trial, in collaboration with Merck KGaA and Pfizer
Inc., of BAVENCIO (avelumab) in combination with MRx0518 as a
first-line maintenance therapy for patients with locally advanced
or metastatic urothelial carcinoma that has not progressed with
first-line platinum-containing chemotherapy, is expected to
commence in Q4 2021.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, and Blautix(R) in Irritable Bowel
Syndrome (IBS) which has completed a successful Phase II trial.
Preclinical-stage programs include candidates for CNS disease such
as Parkinson's disease and other neurodegenerative conditions. The
Company has a research collaboration with MSD, a tradename of Merck
& Co., Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
Contact Information:
4D pharma
Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker +44
(0)20 7496 3000
Philip Davies / Iqra Amin / James Fischer (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUAAWRAWUWRAR
(END) Dow Jones Newswires
August 02, 2021 02:00 ET (06:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024